These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 29741797)

  • 21. Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents.
    Sun J; Wang S; Sheng GH; Lian ZM; Liu HY; Zhu HL
    Bioorg Med Chem; 2016 Nov; 24(21):5626-5632. PubMed ID: 27658794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evaluation as potential anti-inflammatory agents.
    Hassan GS; Abou-Seri SM; Kamel G; Ali MM
    Eur J Med Chem; 2014 Apr; 76():482-93. PubMed ID: 24607877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.
    El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; ElTahir KE
    Bioorg Med Chem; 2012 May; 20(10):3306-16. PubMed ID: 22516672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of substituted benzamides as anti-inflammatory agents that inhibit preferentially cyclooxygenase 1 but do not cause gastric damage.
    Caliendo G; Santagada V; Perissutti E; Severino B; Fiorino F; Warner TD; Wallace JL; Ifa DR; Antunes E; Cirino G; de Nucci G
    Eur J Med Chem; 2001 Jun; 36(6):517-30. PubMed ID: 11525842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1,4-Dihydroquinazolin-3(2H)-yl benzamide derivatives as anti-inflammatory and analgesic agents with an improved gastric profile: Design, synthesis, COX-1/2 inhibitory activity and molecular docking study.
    Sakr A; Kothayer H; Ibrahim SM; Baraka MM; Rezq S
    Bioorg Chem; 2019 Mar; 84():76-86. PubMed ID: 30481648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biologic evaluation of substituted 5-methyl-2-phenyl-1H-pyrazol-3(2H)-one derivatives as selective COX-2 inhibitors: molecular docking study.
    Dube PN; Bule SS; Mokale SN; Kumbhare MR; Dighe PR; Ushir YV
    Chem Biol Drug Des; 2014 Oct; 84(4):409-19. PubMed ID: 24636540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aryl/heteroaryl Substituted Celecoxib Derivatives as COX-2 Inhibitors: Synthesis, Anti-inflammatory Activity and Molecular Docking Studies.
    Madhava G; Ramana KV; Sudhana SM; Rao DS; Kumar KH; Lokanatha V; Rani AU; Raju CN
    Med Chem; 2017; 13(5):484-497. PubMed ID: 28228088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and anti-inflammatory assessment of certain substituted 1,2,4-triazoles bearing tetrahydroisoquinoline scaffold as COX 1/2-inhibitors.
    Abo-Elmagd MI; Hassan RM; Aboutabl ME; Amin KM; El-Azzouny AA; Aboul-Enein MN
    Bioorg Chem; 2024 Sep; 150():107577. PubMed ID: 38941697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of novel 4-fluorobenzamide-based derivatives as promising anti-inflammatory and analgesic agents with an enhanced gastric tolerability and COX-inhibitory activity.
    Halim PA; Georgey HH; George MY; El Kerdawy AM; Said MF
    Bioorg Chem; 2021 Oct; 115():105253. PubMed ID: 34390973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of novel 1,2,3-triazole based benzoxazolinones: their TNF-α based molecular docking with in-vivo anti-inflammatory, antinociceptive activities and ulcerogenic risk evaluation.
    Haider S; Alam MS; Hamid H; Shafi S; Nargotra A; Mahajan P; Nazreen S; Kalle AM; Kharbanda C; Ali Y; Alam A; Panda AK
    Eur J Med Chem; 2013; 70():579-88. PubMed ID: 24211633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study.
    Moussa G; Alaaeddine R; Alaeddine LM; Nassra R; Belal ASF; Ismail A; El-Yazbi AF; Abdel-Ghany YS; Hazzaa A
    Eur J Med Chem; 2018 Jan; 144():635-650. PubMed ID: 29289887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
    Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
    Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors.
    Murahari M; Mahajan V; Neeladri S; Kumar MS; Mayur YC
    Bioorg Chem; 2019 May; 86():583-597. PubMed ID: 30782576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational Design and Synthesis of Benzamides as Non-ulcerogenic Anti-inflammatory Agents.
    Khadse S; Ugale V; Talele G
    Antiinflamm Antiallergy Agents Med Chem; 2015; 13(3):174-87. PubMed ID: 25323059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Inflammatory Activity of Novel 12-N-methylcytisine Derivatives.
    Tsypysheva IP; Borisevich SS; Zainullina LF; Makara NS; Koval'skaya AV; Petrova PR; Khursan SL; Vakhitova YV; Zarudii FS
    Antiinflamm Antiallergy Agents Med Chem; 2017; 16(2):112-122. PubMed ID: 28618989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of novel triarylpyrazoline derivatives as selective COX-2 inhibitors.
    Abdellatif KR; Abdelgawad MA; Labib MB; Zidan TH
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5787-91. PubMed ID: 26546221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory activity of anti-hyperlipidemic drug, fenofibrate, and its phase-I metabolite fenofibric acid: in silico, in vitro, and in vivo studies.
    Prasad GS; Govardhan P; Deepika G; Vakdevi V; Sashidhar RB
    Inflammopharmacology; 2018 Aug; 26(4):973-981. PubMed ID: 29238904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New benzimidazothiazole derivatives as anti-inflammatory, antitumor active agents: Synthesis, in-vitro and in-vivo screening and molecular modeling studies.
    El-Kerdawy MM; Ghaly MA; Darwish SA; Abdel-Aziz HA; Elsheakh AR; Abdelrahman RS; Hassan GS
    Bioorg Chem; 2019 Mar; 83():250-261. PubMed ID: 30391698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
    Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
    Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
    Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
    Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.